Eli Lilly: insulin glargine approved in Egypt
(CercleFinance.com) - Eli Lilly has announced that the Egyptian Medicines Authority has approved the insulin glargine injection manufactured by EVA Pharma in collaboration with Eli Lilly and Company.
This collaboration, launched in 2022, aimed to provide high-quality, affordable human and analog insulin to at least one million people living with type 1 and type 2 diabetes in low- and middle-income countries, mainly in Africa.
This approval marks the first regulatory approval of EVA Pharma's insulin products, following the agreement signed in December 2022 with Lilly, which supplies the active pharmaceutical ingredient at a reduced price and provides technology transfer.
This collaboration is part of the Lilly 30x30 initiative, aimed at improving access to healthcare for 30 million people in resource-limited settings by 2030.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
This collaboration, launched in 2022, aimed to provide high-quality, affordable human and analog insulin to at least one million people living with type 1 and type 2 diabetes in low- and middle-income countries, mainly in Africa.
This approval marks the first regulatory approval of EVA Pharma's insulin products, following the agreement signed in December 2022 with Lilly, which supplies the active pharmaceutical ingredient at a reduced price and provides technology transfer.
This collaboration is part of the Lilly 30x30 initiative, aimed at improving access to healthcare for 30 million people in resource-limited settings by 2030.
Copyright (c) 2024 CercleFinance.com. All rights reserved.